Search

Your search keyword '"Trkola, A."' showing total 1,238 results

Search Constraints

Start Over You searched for: Author "Trkola, A." Remove constraint Author: "Trkola, A."
1,238 results on '"Trkola, A."'

Search Results

1. Cohort profile: the Swiss Mother and Child HIV Cohort Study (MoCHiV)

2. Decoupling HIV-1 antiretroviral drug inhibition from plasma antibody activity to evaluate broadly neutralizing antibody therapeutics and vaccines

3. ART-DEX: A novel strategy to monitor broadly neutralizing antibody activity during antiretroviral therapy of HIV-1

5. Trapping the HIV-1 V3 loop in a helical conformation enables broad neutralization

6. Assessing immunogenicity barriers of the HIV-1 envelope trimer

7. How much should we sequence? An analysis of the Swiss SARS-CoV-2 surveillance effort

8. Exploring viral aetiology in upper respiratory tract infections: insights from metagenomic next-generation sequencing in Swiss outpatients before and during the SARS-CoV-2 pandemic

9. Assessing immunogenicity barriers of the HIV-1 envelope trimer

10. Africa-specific human genetic variation near CHD1L associates with HIV-1 load

12. Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland

13. Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection

14. Long-term course of neutralising antibodies against SARS-CoV-2 in vaccinated and unvaccinated staff and residents in a Swiss nursing home: a cohort study 2021–2022

15. Bridging the gap: identifying factors impacting mRNA severe acute respiratory syndrome coronavirus 2 vaccine booster response in people with HIV-1

17. Mechanisms and clinical relevance of the bidirectional relationship of viral infections with metabolic diseases

18. Viral suppression and retention in HIV care during the postpartum period among women living with HIV: a longitudinal multicenter cohort study

19. Revealing viral and cellular dynamics of HIV-1 at the single-cell level during early treatment periods

20. External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection

21. Viral suppression and retention in HIV care during the postpartum period among women living with HIV: a longitudinal multicenter cohort studyResearch in context

22. Author Correction: Africa-specific human genetic variation near CHD1L associates with HIV-1 load

24. Impact of hormonal therapy on HIV‐1 immune markers in cis women and gender minorities.

25. Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity

26. Distinct conformations of the HIV-1 V3 loop crown are targetable for broad neutralization

27. A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®

28. Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA

29. High-dimensional immune phenotyping of blood cells by mass cytometry in patients infected with hepatitis C virus

30. Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection

31. How much should we sequence? An analysis of the Swiss SARS-CoV-2 surveillance effort

32. Deciphering factors linked with reduced SARS-CoV-2 susceptibility in the Swiss HIV Cohort Study

33. Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration

34. Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response

35. Do we cause false positives? An experimental series on droplet or airborne SARS-CoV-2 contamination of sampling tubes during swab collection in a test center

36. Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection

37. Long-term course of neutralising antibodies against SARS-CoV-2 in vaccinated and unvaccinated staff and residents in a Swiss nursing home: a cohort study 2021–2022

40. Distinct conformations of the HIV-1 V3 loop crown are targetable for broad neutralization

42. Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity

43. Evolution of SARS-CoV-2 seroprevalence and clusters in school children from June 2020 to April 2021: prospective cohort study Ciao Corona

44. Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response

45. Variation in SARS-CoV-2 seroprevalence across districts, schools and classes: baseline measurements from a cohort of primary and secondary school children in Switzerland

46. Bridging the Gap: identifying factors impacting mRNA SARS-CoV-2 vaccine booster response in people living with HIV-1

47. The TransFLUas influenza transmission study in acute healthcare - recruitment rates and protocol adherence in healthcare workers and inpatients

48. Structure of HIV-1 gp41 with its membrane anchors targeted by neutralizing antibodies

49. SARS-CoV-2 variants reveal features critical for replication in primary human cells.

50. Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation

Catalog

Books, media, physical & digital resources